XXXX and breast feeding.

@entity1 @entity1089
OBJECTIVE: To quantify the relative @entity1 dose of @entity1089 during breast feeding, describe the milk:plasma (M:P) ratio, and determine the well-being of the exposed @entity1 . CASE SUMMARY: A 26-year-old mother and her 3-month-old son were studied over a 24 hour @entity1089 dose interval at steady-state. @entity1089 concentrations were quantified by high-performance liquid chromatography. @entity1 exposure was calculated as the concentration in milk multiplied by an estimated milk production of 0.15 L/kg/day and normalized to the weight-adjusted maternal dose. The average concentration in milk was 41 microg/L, the M:P ratio (measured using average concentrations in the elimination phase) was 0.29, and the relative @entity1 dose was 0.09% of the maternal weight-adjusted dose (7273 microg/kg/day). The @entity1 plasma concentration of 1.4 microg/L was some 6% of the corresponding maternal plasma concentration. No adverse effects were noted in the @entity1 . DISCUSSION: Our findings of an @entity1 exposure to @entity1089 of less than 0.1% of the maternal dose and a lack of adverse effects confirm and extend the findings of 2 previous studies. CONCLUSIONS: Although limited, the data shown here support the prescription of @entity1089 to a breast-feeding mother following a careful individual risk/benefit analysis. We suggest regular monitoring of @entity1 progress and occasional measurement of @entity1089 in the @entity1 's plasma.
